Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)

- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects

- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Arch Biopartners Inc

Atox Bio Ltd

Balmes Transplantation SAS

Cellmid Ltd

CFM Pharma ...

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Arch Biopartners Inc

Atox Bio Ltd

Balmes Transplantation SAS

Cellmid Ltd

CFM Pharma Holding BV

Cypralis Ltd

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

F. Hoffmann-La Roche Ltd

GeneScience Pharmaceuticals Co Ltd

Klotho Therapeutics Inc

Kringle Pharma Inc

Mitobridge Inc

Mitotech SA

Pharmicell Co Ltd

Quark Pharmaceuticals Inc

Radikal Therapeutics Inc

Redx Pharma Plc

Silver Creek Pharmaceuticals Inc

Spherium Biomed SL

STATegics Inc

Torrent Pharmaceuticals Ltd

vasopharm GmbH

Xigen SA

Table of Contents

Table of Contents

Introduction

Acute Renal Failure (ARF) (Acute Kidney Injury) – Overview

Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Development

Acute Renal Failure (ARF ...

Table of Contents

Introduction

Acute Renal Failure (ARF) (Acute Kidney Injury) – Overview

Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Development

Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Assessment

Acute Renal Failure (ARF) (Acute Kidney Injury) – Companies Involved in Therapeutics Development

Acute Renal Failure (ARF) (Acute Kidney Injury) – Drug Profiles

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects

Acute Renal Failure (ARF) (Acute Kidney Injury) – Discontinued Products

Acute Renal Failure (ARF) (Acute Kidney Injury) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2019

Number of Products under Development by Companies ...

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by A1M Pharma AB, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Alloksys Life Sciences BV, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Am-Pharma BV, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Angion Biomedica Corp, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by CFM Pharma Holding BV, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Cypralis Ltd, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by DURECT Corp, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Evotec AG, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Exponential Biotherapies Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by GeneScience Pharmaceuticals Co Ltd, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Klotho Therapeutics Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Kringle Pharma Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mitobridge Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mitotech SA, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Pharmicell Co Ltd, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Quark Pharmaceuticals Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Radikal Therapeutics Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Redx Pharma Plc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Silver Creek Pharmaceuticals Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Spherium Biomed SL, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by STATegics Inc, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Torrent Pharmaceuticals Ltd, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by vasopharm GmbH, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Xigen SA, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, H1 2019 (Contd..1), H1 2019

Acute Renal Failure (ARF) (Acute Kidney Injury) – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2019

Number of Products under Development by Companies ...

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports